Navigation Links
Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
Date:8/24/2010

Warner Chilcott Announces Receipt of FDA Response to Citizen Petition -- ARDEE, Ireland, Aug. 24 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Warner Chilcott Announces Receipt of FDA Response to Citizen Petition

 

ARDEE, Ireland, Aug. 24 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has received the Food and Drug Administration's ("FDA's") response to a citizen petition it had filed regarding its ASACOL and ASACOL HD products.  In its petition, Warner Chilcott requested that the FDA (1) issue bioequivalence guidance for mesalamine delayed-release tablets, (2) not approve any abbreviated new drug applications ("ANDAs") referencing ASACOL and/or ASACOL HD unless the proposed generic product is shown to be bioequivalent based on appropriate data from a clinical efficacy endpoint study, comparative pharmacokinetic testing and rigorous in vitro dissolution testing and (3) deny any waiver of bioequivalence testing for either ASACOL or ASACOL HD based on a showing of bioequivalence in the other strength.  In its joint-response to the citizen petitions of the Company and another petitioner, the FDA has granted in part and denied in part various aspects of the citizen petitions.  The impact of the FDA's response will depend upon the particular facts of any ANDA filed referencing ASACOL and/or ASACOL HD.

A copy of the FDA's response letter is available in the Investor Relations section of the Company's website at www.wcrx.com.  In addition, the Company's citizen petition and related information and the FDA's response letter are, or will be made available, on the www.regulations.gov website.

About Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-G.

Forward Looking Statements This press release contains forward-looking statements, including statements concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts.  These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.  These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.  The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur.  We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... July 14, 2017 Endo International plc (NASDAQ: ... August 8, 2017.  Members of its senior management team will host ... at 8:30 a.m. ET. The dial-in number to ... International (678) 509-7598, and the passcode is 45397076. Please dial in ... A replay of the call will be ...
(Date:7/13/2017)... , July 13, 2017  New York City-based market research ... markets should be aware of.  From new products to new ... detailed in a recently completed study, Potential Pipeline Disruptors ... 1.  Age-Driven Growth - True ... been aware of the impact the growing population and, to ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Winner for its Product Innovation in the prestigious CEO World Awards®. The coveted ... performance, new products and services, CEO case studies, corporate social responsibility, and milestones ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South Austin is ... 24 Hours a day. , The Emergency Room opened early March, ... open four months now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency ...
(Date:7/24/2017)... PARK (PRWEB) , ... July 24, 2017 , ... Engineers ... is bio-compatible, because it produces the same kind of electrical energy that the body ... the form of moving electrons. This flow of electrons out of the battery is ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P ... of the new Destination Medical Building located at Mayo Clinic in Jacksonville, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
Breaking Medicine News(10 mins):